ONC compared with GRAL: revenue, margins and what each company keeps, and the suppliers and customers both name

ONCBeOne Medicines Ltd.

Mkt capRevenueRevenue

GRALGrail, Inc.

Mkt capRevenueRevenue

Compare

ONCBeOne Medicines Ltd.

GRALGrail, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

ONC1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▼−0.15%—

GRAL

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±14.1%▼−14.53%×1.03

Q1 FY26±13.3%▲+15.35%×1.15

= impliedONC realized, solidGRAL realized, hatchedOne scale, both sides: full bar = 51%× = |realized| ÷ impliedSource: market data

Feb 20 '26

±7.3%

▼−50.55%

×6.92

Jan 12 '26±9.5%▲+5.82%×0.61

ONCBeOne Medicines Ltd.

368.02▼−0.62%· post 361.81

Mkt cap$41.1BRevenue$1.7BQ2 FY26Revenue$5.3BFY25

GRALGrail, Inc.

133.35▼−7.03%· post 134.66

ClosedNov 2 '26

Mkt cap$6.0BRevenue$45MQ2 FY26Revenue$147MFY25

Compare

ClosedNov 2 '26

ONCBeOne Medicines Ltd.

GRALGrail, Inc.

368.02▼−0.62%post 361.81

Price

133.35▼−7.03%post 134.66

$41.1B

Mkt cap

$6.0B

Q2 FY26$1.7B

Revenue

$45MQ2 FY26

FY25$5.3B

Revenue

$147MFY25

ONC368.02▼−0.62%vsGRAL133.35▼−7.03%ClosedNov 2 '26